Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes.
about
Dronedarone-current status in management of atrial fibrillationBeta1-adrenoceptor polymorphism predicts flecainide action in patients with atrial fibrillation.Effects of amiodarone on short QT syndrome variant 3 in human ventricles: a simulation study.Effect of dronedarone on Na+, Ca2+ and HCN channels.Effects of the novel amiodarone-like compound SAR114646A on cardiac ion channels and ventricular arrhythmias in rats.Reduction of cerebral infarct size by dronedarone.Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy.Dronedarone: an amiodarone analogue.A review of the pharmacokinetics, electrophysiology and clinical efficacy of dronedarone.Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter.Review of the current management of atrial fibrillation.Dronedarone: an emerging agent with rhythm- and rate-controlling effects.A review of the investigational antiarrhythmic agent dronedarone.Pharmacologic targets for atrial fibrillation.Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues.Dronedarone: in quest of the ideal antiarrhythmic drug.Dronedarone for atrial fibrillation: a new therapeutic agent.Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation.New developments in atrial antiarrhythmic drug therapy.Optimizing the management of atrial fibrillation: focus on current guidelines and the impact of new agents on future recommendations.Drug-induced QT-interval prolongation: considerations for clinicians.A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission.Dronedarone as a new treatment option for atrial fibrillation patients: pharmacokinetics, pharmacodynamics and clinical practice.Dronedarone for atrial fibrillation therapy.Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.Dronedarone: Where Does it Fit in the AF Therapeutic Armamentarium?Dronedarone in the management of atrial fibrillation.Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria.Dose-dependent effects of oral dronedarone on the circadian variation of RR and QT intervals in healthy subjects: implications for antiarrhythmic actions.In vitro effects of acute amiodarone and dronedarone on epicardial, endocardial, and M cells of the canine ventricle.Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels.In vivo Analysis of the Anti-atrial Fibrillatory, Proarrhythmic and Cardiodepressive Profiles of Dronedarone as a Guide for Safety Pharmacological Evaluation of Antiarrhythmic Drugs.In-silico assessment of the dynamic effects of amiodarone and dronedarone on human atrial patho-electrophysiology.Dronedarone and digitalis: individually reduced post-repolarization refractoriness enhances life-threatening arrhythmias.Pharmacological Therapy in Brugada Syndrome.A Cardiac Cell Outgrowth Assay for Evaluating Drug Compounds Using a Cardiac Spheroid-on-a-Chip Device.
P2860
Q27001666-3B5316D7-D90C-4248-ADA8-C53E79642B65Q33631107-597E6B52-6828-423C-B265-A3CB1A6192DAQ33776456-97F20392-7A80-424A-9236-DE421E225FD4Q33807062-91ABDFCD-CBEA-45F8-B4E5-116BE567A94AQ33964046-6F2E2C57-330B-4B69-A6F2-63698E3D0B82Q34007040-B9969409-A921-49C1-BD92-25F61EC6EB1AQ34068742-9A45825C-EB29-4E6A-AAC2-7D5846A1201CQ34315512-4927192A-16D4-47CF-85E3-2485C6EEFDC0Q34612472-7FD119F7-6067-48EB-B720-E9BF091D6EE5Q35440513-B7C719C8-9340-4496-80CF-FEFEAC64387AQ35574957-1FE88295-76A6-4157-B78D-65CD9E68C782Q36580662-044699A6-D2A6-4C62-A67B-72991BF39D34Q36818238-59016307-B871-43D3-A1E4-E56F734F8BE4Q36936338-2D95026F-B94C-47B6-97DC-A1BD05F63F18Q36964943-5D1F0F41-70E6-4310-AA4D-107CCEE75275Q37024385-4DD68704-4363-4539-B898-C2B39804EEC9Q37302482-AC23DAA5-FF3F-49EC-BEC6-8049038859F5Q37584282-A788F551-7D92-4AFD-8EE8-70E1BECAD642Q37697498-FFC016B0-B87D-415D-AE2A-5D021E5FF2BCQ37766393-E2BA8EBF-6A1D-4F8C-8F35-4FD41FE3606DQ37767425-F2E8DAE2-76DC-4483-BA68-5B9650D9FE38Q37811683-D4C5CEF1-9B20-4D84-90F9-1A2AA4E7423DQ37815205-0D9EE1D7-214D-40C9-8E1F-11FEB84FCFA0Q37895677-DDFD861F-C219-470B-B72D-A47E2A45A511Q38074906-AE316DC7-F823-4981-982F-12BACE5587F2Q38790548-35A772FC-5164-4153-BFFA-65613958BB1AQ38826285-40E7DD7A-37DC-459A-8CED-59CB0D8750EAQ42432616-8FFEC7B6-F04B-4437-BE7D-9D399DFDD455Q46111350-101D5A16-E63A-477E-B09D-572C3B7D8960Q46825552-7A1A206D-1053-4B99-9A26-BFF86DB6A0C7Q48644420-7D30CC7C-AFED-4EBF-9F3E-64E28EEBA791Q50012784-731E9932-405F-438E-AD5B-51223447EAE6Q51017616-D17EF8F1-3519-48AB-BCF8-DBAB2CB10DCDQ51051828-A77CF47C-36A1-4AA9-BF97-A8C01E4C871EQ55415521-11C88A9B-8107-4E30-8B2E-D830447BE8D3Q55687817-842B179C-5DD9-4C64-86D4-AC48FD054E35
P2860
Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Effects of amiodarone and dron ...... rrent in human cardiomyocytes.
@en
Effects of amiodarone and dron ...... rrent in human cardiomyocytes.
@nl
type
label
Effects of amiodarone and dron ...... rrent in human cardiomyocytes.
@en
Effects of amiodarone and dron ...... rrent in human cardiomyocytes.
@nl
prefLabel
Effects of amiodarone and dron ...... rrent in human cardiomyocytes.
@en
Effects of amiodarone and dron ...... rrent in human cardiomyocytes.
@nl
P2093
P2860
P1476
Effects of amiodarone and dron ...... rrent in human cardiomyocytes.
@en
P2093
Joël Nargeot
Nathalie Lalevée
Patrick Gautier
Stéphanie Barrére-Lemaire
Sylvain Richard
P2860
P304
P356
10.1046/J.1540-8167.2003.03064.X
P577
2003-08-01T00:00:00Z